NASDAQ OMX

BIMobject AB: BIMobject becomes a key sponsor at industry convention in Las Vegas

Dela

Today, BIMobject AB (publ) ("BIMobject") announces that the company is one of the biggest sponsors of the annual industry convention Autodesk University ("AU") in Las Vegas. BIMobject will host a seminar and occupy the largest booth of the participating exhibitors to demonstrate its innovative solutions. AU draws more than 10,000 experts from the architecture, design, manufacturing, and media industries. This year's convention is held November 14-16 and will explore the future of making things.

As a Gold sponsor of the event, BIMobject collaborates with Autodesk at their AU convention. This year's event will explore the evolution of design and engineering technology, as well as how day-to-day innovations and efficiencies are the bridge to the future. In this spirit, BIMobject participates with a focus on interactivity and involvement - not just as an exhibitor, but as an educator as well: The company's leading expert on the topic will show how the solution BIMscript® & LENA lets its users create their own parametric, digital building objects. 

World leading experts will also be present in the large BIMobject booth in order to share their knowledge about the future of the building industry. Visitors will be able to try out the company's groundbreaking Virtual Reality-solutions, and experience the advantages of the various design and sales tools connected to the platform BIMobject® Cloud through innovative visualisation technology. 

Another focus for BIMobject during the convention will be to assist former Autodesk SEEK users and illustrate the value added to the service since it became a BIMobject offering at the beginning of 2017.

"It's great to be able to take such a leading role in a context that gathers a large number of different businesses. BIMobject have worked closely with Autodesk before, even beyond the transfer of SEEK. For example, our platform BIMobject ® Cloud is compatible with their solutions Autodesk Revit, Autodesk AutoCAD, Forge, and Fusion 360. Having made these good experiences, we continue to drive the digital development of the construction industry together", says Stefan Larsson, CEO and founder of BIMobject.

More information about AU can be found on the event website.

For more information, please contact: 
Louise Otto - Press contact
Tel: +46 40 - 685 29 00 
E-mail: press@bimobject.com

About BIMobject ®
The BIMobject® corporation, acknowledged by investors with a Global Red Herring 100 award, and a public company on Nasdaq Stockholm First North: ticker symbol BIM. BIMobject® is a game changer for the construction industry worldwide with its cloud based digital content management system for BIM objects. 

BIMobject as a disruptive technology corporation is at the forefront of the digitalisation of building products and materials, enabling the information to be turned into know-how earlier in the BIM process. The BIMobject® Cloud is a digital platform where BIM professionals can find and download BIM files from brands, from both Europe and US. This will enable industrialisation of the construction industry and also have a huge impact on design, product selection, constructability, waste, energy, cost, quality, and logistics.

Our unique solutions for building product manufacturers provide development, hosting, maintenance, syndication, and publication of the digital replicas of the manufacturers' products - BIM objects. The marketing and pre-sales services associated with the BIMobject® Cloud are channelled and integrated, through Apps, into CAD/BIM applications to create a business-to-business communication across the globe.

Manufacturers use BIMobject® to promote and deliver their products directly into BIM processes, enabling their products to be selected and generate a real improvement in sales.

Certified Adviser: Sedermera Fondkommission

bimobject.com 

This is an English version of an original Swedish press release communicated by BIMobject AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply.

Autodesk, AutoCAD, Forge, Fusion 360 and Revit are registered trademarks or trademarks of Autodesk, Inc., and/or its subsidiaries and/or affiliates in the USA and/or other countries.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BIMobject AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum